La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.
OBJECTIVES: Risk of severe respiratory syncytialvirus (RSV) disease is increased among adults with cardiopulmonary disease. This study modeled the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults ≥60 years of age (YOA) with specific prevalent cardiopulmonary diseases.